Pre-term Premature Rupture of Membranes
14
0
0
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
7.1%
1 terminated out of 14 trials
85.7%
-0.8% vs benchmark
14%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Unlocking New Avenues: Azithromycin Vs Erythromycin in Pre-term, Pre-mature Rupture of Membrane Management
Cervical Ripening in Premature Rupture of Membranes
Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 Levels in PPROM
Matrix Metalloproteinase 14, Neopterin, and Orosomucoid 1 Levels in PPROM
Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes
Magnesium Sulfate Versus Placebo for Tocolysis in PPROM
The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes
Preterm Premature Rupture of Membranes, Outpatient Management vs Inpatient Management
Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)
Preterm Premature Rupture of Membranes (PPROM): Bed Rest Versus Activity Trial
PPROM Erythromycin Versus Azithromycin
Pomegranate to Reduce Maternal and Fetal Oxidative Stress and Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of the Membranes
Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study
Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery